Humana Inc. (HUM)
| Market Cap | 33.01B +2.2% |
| Revenue (ttm) | 137.20B +14.1% |
| Net Income | 1.13B -33.9% |
| EPS | 9.36 -33.9% |
| Shares Out | 120.06M |
| PE Ratio | 29.38 |
| Forward PE | 26.04 |
| Dividend | $3.54 (1.29%) |
| Ex-Dividend Date | Jun 26, 2026 |
| Volume | 3,151,710 |
| Open | 250.00 |
| Previous Close | 247.12 |
| Day's Range | 247.50 - 274.97 |
| 52-Week Range | 163.11 - 315.35 |
| Beta | 0.68 |
| Analysts | Hold |
| Price Target | 248.25 (-9.71%) |
| Earnings Date | Apr 29, 2026 |
About HUM
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and... [Read more]
Financial Performance
In 2025, Humana's revenue was $129.66 billion, an increase of 10.11% compared to the previous year's $117.76 billion. Earnings were $1.19 billion, a decrease of -1.57%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for HUM stock is "Hold." The 12-month stock price target is $248.25, which is a decrease of -9.71% from the latest price.
News
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Florida Seniors Face High Rates of Poor Mental Health -- A Looming Crisis as State Braces for Aging Population Boom
LOUISVILLE, Ky.--(BUSINESS WIRE)--Florida ranks among the top three states in the nation for the largest senior population, with projections showing that one-third of its residents will be over 60 by ...
Major health insurers show signs of recovery – but a key test looms
Solid first-quarter results from major insurers like UnitedHealth, Elevance, Cigna and Humana have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. But a...
Humana price target raised to $211 from $173 at TD Cowen
TD Cowen raised the firm’s price target on Humana (HUM) to $211 from $173 and keeps a Hold rating on the shares. The firm said adj EPS $10.31 beat conensus
Humana price target raised to $214 from $180 at JPMorgan
JPMorgan raised the firm’s price target on Humana (HUM) to $214 from $180 and keeps a Neutral rating on the shares.
Humana price target raised to $260 from $230 at Raymond James
Raymond James raised the firm’s price target on Humana (HUM) to $260 from $230 and keeps an Outperform rating on the shares. Humana delivered slightly better-than-expected Q1 results with an
Humana price target raised to $260 from $250 at Oppenheimer
Oppenheimer raised the firm’s price target on Humana (HUM) to $260 from $250 and keeps an Outperform rating on the shares. The firm notes Humana reported a solid Q1 beat,
Humana price target raised to $195 from $158 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Humana (HUM) to $195 from $158 and keeps a Sell rating on the shares. Humana rose after a modest Q1 earnings beat
Humana price target raised to $250 from $195 at Evercore ISI
Evercore ISI analyst Elizabeth Anderson raised the firm’s price target on Humana (HUM) to $250 from $195 and keeps an In Line rating on the shares.
Humana price target raised to $235 from $180 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Humana (HUM) to $235 from $180 and keeps a Hold rating on the shares.
Humana price target raised to $246 from $189 at RBC Capital
RBC Capital analyst Ben Hendrix raised the firm’s price target on Humana (HUM) to $246 from $189 and keeps a Sector Perform rating on the shares after its Q1 earnings
Humana price target raised to $270 from $220 at Truist
Truist analyst David MacDonald raised the firm’s price target on Humana (HUM) to $270 from $220 and keeps a Hold rating on the shares. The company reported solid Q1 results,
Humana price target raised to $262 from $195 at UBS
UBS raised the firm’s price target on Humana (HUM) to $262 from $195 and keeps a Neutral rating on the shares. The update reflects an improved Medicare Advantage final rate
Humana price target raised to $269 from $252 at Guggenheim
Guggenheim raised the firm’s price target on Humana (HUM) to $269 from $252 and keeps a Buy rating on the shares after the company reported Q1 EPS upside on favorable
Humana price target raised to $180 from $176 at Barclays
Barclays raised the firm’s price target on Humana (HUM) to $180 from $176 and keeps an Equal Weight rating on the shares.
Humana Earnings Call Transcript: Q1 2026
First quarter results met expectations, with strong MA and Medicaid membership growth and prudent reserving. Progress continues toward a 3%+ margin by 2028, aided by operational efficiencies, cost management, and strategic acquisitions.
Humana Profits Eclipse $1 Billion As Medicare Costs Ease Slightly
Humana reported first quarter net income of nearly $1.2 billion as costs of care for older adults in its Medicare Advantage plans eased a bit but remained high.
Humana Profit Falls as Lower Medicare Ratings Hurt Bonuses
Humana reported lower first-quarter profit as the company faces earnings headwinds from lower Medicare Advantage Star Ratings for 2026.
Humana beats quarterly profit estimates on lower medical costs
Humana on Wednesday beat Wall Street estimates for first-quarter profit as the health insurer spent less on medical services than expected.
Humana reports Q1 adjusted EPS $10.31, consensus $10.20
“We’ve had a solid start to the year and feel good about how our operating execution and transformation initiatives are setting us up for the future,” said Humana (HUM) President
Humana backs FY26 adjusted EPS view ‘at least’ $9.00, consensus $8.71
06:01 EDT Humana (HUM) backs FY26 adjusted EPS view ‘at least’ $9.00, consensus $8.71
Humana Reports First Quarter 2026 Financial Results; Affirms Full Year 2026 Adjusted Financial Guidance
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended March 31, 2026 (1Q26) versus the quarter...
Humana Earnings Could Signal If More Medicare Advantage Members Is a Good Thing
The stock has slumped this year, seesawing on news of how much the government plans to pay insurers that operate Medicare Advantage health plans for seniors.
Humana partners with Mark Cuban's Cost Plus Drugs on technology, distribution
Humana announced on Monday it will launch a pharmacy partnership with Mark Cuban's Cost Plus Drugs, with the health conglomerate's CenterWell pharmacy unit serving as a distributor for the platform.
Humana CenterWell announces partnership with Mark Cuban Cost Plus Drug Company
CenterWell Pharmacy, a part of Humana (HUM), announced a deepened partnership with Mark Cuban Cost Plus Drug Company to develop new, end-to-end employer prescription solutions. As part of this collabo...